Register Login
Register to leave comments
  • News bot Aug. 27, 2026, 8:29 p.m.

    🔍 Wagner Paul A. (Executive)

    Company: Forte Biosciences, Inc. (FBRX)

    Report Date: 2026-08-27

    Transaction Summary:

    • Total transactions: 11
    • Derivative instruments: 10
    • Holdings reported: 0
    • Total shares sold: 2,039,758

    Detailed Transactions and Holdings:

    • Sold 85,482 shares of Common Stock (Direct)
      Date: 2026-08-27 | Code: U | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
    • Sold 16,866 shares of Stock Option (right to buy) at $21.5 per share (Derivative)
      Date: 2026-08-27 | Code: D | Expires: 2028-12-19 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2
    • Sold 5,400 shares of Stock Option (right to buy) at $991.5 per share (Derivative)
      Date: 2026-08-27 | Code: D | Expires: 2031-04-09 | Exercise: 2025-04-09 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2
    • Sold 11,999 shares of Stock Option (right to buy) at $43.0 per share (Derivative)
      Date: 2026-08-27 | Code: D | Expires: 2032-01-17 | Exercise: 2026-01-17 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2
    • Sold 44,000 shares of Stock Option (right to buy) at $17.25 per share (Derivative)
      Date: 2026-08-27 | Code: D | Expires: 2034-03-21 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2
    • Sold 920,000 shares of Stock Option (right to buy) at $7.54 per share (Derivative)
      Date: 2026-08-27 | Code: D | Expires: 2035-03-20 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2
    • Sold 270,000 shares of Stock Option (right to buy) at $29.66 per share (Derivative)
      Date: 2026-08-27 | Code: D | Expires: 2036-01-12 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2
    • Sold 500,000 shares of Stock Option (right to buy) at $17.15 per share (Derivative)
      Date: 2026-08-27 | Code: D | Expires: 2036-06-16 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2
    • Sold 2,500 shares of Restricted Stock Units (Derivative)
      Date: 2026-08-27 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F4, F4, F4
    • Sold 180,000 shares of Restricted Stock Units (Derivative)
      Date: 2026-08-27 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F4, F4, F4
    • Sold 3,511 shares of Restricted Stock Units (Derivative)
      Date: 2026-08-27 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F4, F4, F4

    Footnotes:

    • F1: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $77.00 per share ("Merger Consideration"), net to the seller in cash, without interest, subject to any required withholding tax. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.
    • F2: Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger. At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
    • F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock.
    • F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger.
    • REMARKS: CEO, Secretary and Chair of the Board

Search

News categories